AVITA Medical (ASX: AVH) Shares RiseS on Leadership Clarity

Sonal Goyal

01 May 2026 12:32 PM AEST

AVITA Medical (ASX: AVH) Shares RiseS on Leadership Clarity

Image Source: shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Cary Vance officially appointed as President and CEO of AVITA Medical, effective immediately, following a six-month interim tenure from October 2025.
Jan Stern Reed simultaneously appointed as Chair of the Board, replacing the previous lead independent director structure.
AVH shares gained AUD 0.035, or 2.88%, to trade at AUD 1.25 on 1 May 2026, reflecting positive market reception of the Leadership announcement.

AVITA Medical (ASX:AVH) (Nasdaq:RCEL) shares advanced AUD 0.035, or 2.88%, to trade at AUD 1.25 on 1 May 2026, making it one of the stronger performers among ASX-listed healthcare companies on the day. The positive price movement came in direct response to the company's announcement confirming the permanent appointment of Cary Vance as President and Chief Executive Officer. The market's reaction reflects relief that a period of Leadership uncertainty — which began when Vance stepped in on an interim basis in October 2025 — has been resolved with a clear, unanimous and permanent decision from the board. Leadership stability is highly valued in medical technology companies where commercial execution, regulatory relationships and investor confidence are closely intertwined.

The Appointment: Resolving Six Months of Leadership Transition

The announcement, dated 30 April 2026 and made effective immediately, concludes a Leadership transition process that commenced in October 2025 when Vance was first appointed as Interim CEO. The board's decision to make the appointment permanent followed a thorough search process conducted in coordination with a top-tier international executive search firm. According to incoming Chair Jan Stern Reed, the board was unanimous in its conclusion that Vance represented the right leader on a permanent basis, having demonstrated decisive Leadership, operational discipline, and deep industry understanding during the six-month interim period.

In addition to the CEO appointment, the board simultaneously effected a governance change, appointing Jan Stern Reed as Chair of the AVITA Medical Board. Her predecessor role as Lead Independent Director was discontinued as part of this transition. These two moves together represent a meaningful evolution of the company's Leadership structure, providing clarity at both the executive and non-executive levels of governance.

Who Is Cary Vance?

Cary Vance brings an extensive background in medical technology commercialisation and executive Leadership. He has served on the AVITA Medical Board of Directors since 2023 and held the position of Chairman in 2025. Before his appointment as Interim CEO in October 2025, Vance had accumulated 30 years of healthcare industry experience across multiple chief executive roles, including at PhotoniCare, Titan Medical, OptiScan Biomedical, MyoScience, Hansen Medical and XCath. Earlier in his career he held senior Leadership positions at Teleflex, Covidien and GE HealthCare — three of the most prominent names in the global medical device and healthcare technology sector.

This depth of experience in commercialising innovative medical technologies is particularly well-suited to AVITA Medical's current strategic posture. The company is transitioning from being primarily a wound care innovator to a broader acute wound care platform Business with expanding commercial reach, and Vance's track record in navigating precisely these kinds of growth-phase transitions will be closely watched by investors.

Who Is Jan Stern Reed?

Jan Stern Reed's elevation to Chair adds further depth to AVITA Medical's governance structure. A board member since 2021, Reed brings over 35 years of legal and Business management experience in the healthcare sector, accumulated through both executive Leadership and non-executive directorship roles. Her continuity on the board — transitioning from Lead Independent Director to Chair — ensures that the governance transition does not disrupt institutional knowledge or stakeholder relationships built over the past several years.

Context: AVITA Medical's Strategic Position

AVITA Medical describes itself as a leading therapeutic acute wound care company. Its flagship product platform — built on the RECELL technology — has received regulatory clearances and has been commercialised primarily in the United States. The company operates across both the Nasdaq (as RCEL) and the ASX (as AVH), maintaining a dual listing that provides access to both US and Australian institutional Capital.

During Vance's interim tenure, the company was described as having stabilised its Business operations, sharpened its strategic focus, and rebuilt confidence and enthusiasm with employees, customers and shareholders. These are the foundations of what the board characterised as an incoming growth period. The successful navigation of a Leadership transition — from departure of a prior CEO through an interim appointment and ultimately to a permanent, internally-championed appointment — is a positive signal of organisational continuity and board-level decisiveness.

Q1 FY2026 Earnings Call on the Horizon

AVITA Medical has confirmed that its first quarter 2026 Earnings results will be discussed on 14 May 2026 in the US (15 May 2026 AEST), with a call and webcast scheduled for 1:30 p.m. Pacific Time. This Earnings event will represent Vance's first quarterly results call as permanent CEO, and the market will be looking for detailed operational updates, commercial progress reports, and forward-looking commentary that signals the strategic direction under his permanent Leadership. The proximity of this Earnings Call to the CEO appointment announcement is likely to keep near-term investor attention focused on the upcoming disclosure.

FAQs

Q1. Who is the new CEO of AVITA Medical?

Cary Vance has been appointed as President and Chief Executive Officer of AVITA Medical, effective immediately as of 30 April 2026. He previously served as Interim CEO from October 2025 and has been a board member since 2023. Vance has 30 years of healthcare industry experience across multiple CEO roles in medical technology companies.

Q2. Why did AVITA Medical shares rise on 1 May 2026?

AVH shares rose 2.88% to AUD 1.25 in response to the announcement confirming Cary Vance's permanent appointment as CEO. The market reacted positively to the resolution of a six-month leadership transition, as clarity in the executive suite removes uncertainty that was likely reflected as a discount in the company's share price.

Q3. What is AVITA Medical's core product and market?

AVITA Medical is an acute wound care company whose core platform is based on the RECELL technology, which enables point-of-care skin regeneration for the treatment of burns and other acute wounds. The company is primarily commercialised in the United States and listed on both the NASDAQ (RCEL) and ASX (AVH).

Q4. When will AVITA Medical report its Q1 FY2026 earnings?

AVITA Medical will host its Q1 FY2026 earnings call on 14 May 2026 (US time), equivalent to 15 May 2026 AEST, at 1:30 p.m. Pacific Time. This will be Cary Vance's first quarterly earnings event as permanent CEO.

Q5. Who is Jan Stern Reed and what is her role at AVITA Medical?

Jan Stern Reed has been appointed as Chair of the AVITA Medical Board, effective immediately. She has served on the board since 2021 and brings over 35 years of legal and business management experience in healthcare. She was previously the Lead Independent Director, a role discontinued upon her appointment as Chair.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.